Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Version 1 : Received: 29 September 2020 / Approved: 29 September 2020 / Online: 29 September 2020 (15:09:47 CEST)

How to cite: Harris, L.; Patel, K.; Martin, M. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Preprints 2020, 2020090718 (doi: 10.20944/preprints202009.0718.v1). Harris, L.; Patel, K.; Martin, M. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Preprints 2020, 2020090718 (doi: 10.20944/preprints202009.0718.v1).

Abstract

The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy.1 Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.

Subject Areas

Relapsed or Refractory Diffuse Large B Cell Lymphoma, DLBLC, immunotherapy, chemotherapy-free regimen

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.